Αρχική World News Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients... World News Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC Από Ogkologos - 22 Ιουλίου, 2025 880 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... 9 Φεβρουαρίου, 2023 The Taylor Family Foundation gives £2.1m to support head and neck... 12 Δεκεμβρίου, 2022 Rescued From Complete Darkness 1 Ιουλίου, 2021 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... 7 Αυγούστου, 2024 Φόρτωση περισσοτέρων HOT NEWS A Congress Bag for Women’s Empowerment ¿Cómo están cambiando los requisitos de elegibilidad para los ensayos clínicos... Women Under 35 More Likely to Have Their Breast Cancer Spread Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer...